The treatment of Candesartan joint CSDP on type 2 diabetic nephropathy with stage Ⅲ.
10.3760/cma.j.issn.1008-6315.2012.13.011
- VernacularTitle:坎地沙坦联合复方丹参滴丸治疗2型糖尿病Ⅲ期肾病效果观察
- Author:
Jinping CHEN
;
Xinjun CHOU
;
Zhiying ZHANG
;
Hua YU
;
Yujing LIU
;
Qing CHEN
- Publication Type:Journal Article
- Keywords:
Type 2 diabetes;
Candesartan;
CSDP;
Urinary albumin
- From:
Clinical Medicine of China
2012;(z1):22-23
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effect of CSDP combined with losartan treatment on type 2 diabetic nephropathy with stage Ⅲ.Methods Sixty patients suffered from type 2 diabetic nephropathy with stage Ⅲ were recruited as our subjects.They were randomly divided into Candesartan group and Candesartan + CSDP group,each for 30 patients.Patient in Candesartan + CSDP group were administrated with candesartan 4 mg,once per day,the CSDP 15 capsules and three times / day for 3 months.Patients in Candesartan group were given:candesartan 4 mg once/day for 3 months.The level of urinary albumin,serum urea nitrogen (BUN) and creatinine (Cr) were measured of subjects before and after treatment.Results The levels of BUN,Cr were lower after any treatment than before treatment in 2 groups.The difference of BUN,Cr in Candesartan + CSDP group were(-14.6 ± 8) mg/L,(-11.9 ± 3.3) μmmol/L,(-0.7 ± 0.2) mmol/L,higher than that of Candesartan group (-7.1 ± 7.8) mg/L,(-8.5 ± 0.8) μmol/L,(-0.4 ± 0.1) mmol/L] (P ＜ 0.01).Conclusion The treatment strategy of Candesartan joint CSDP can be method regarding of reducing urinary albumin and BUN,Cr in patients of type 2 diabetic nephropathy with stage Ⅲ.
